Missed seeing any of the VBPS events this year? Good news, the videos are available!
Recordings of the seminars are available at www.boulderpeptide.org/virtual-bps/. *Please note - you must be logged in to the Boulder Peptide website to access the links*
These educational e-seminars are provided free of charge by the Boulder Peptide Foundation. If your company is interested in supporting this or other educational initiatives, please email sponsorship@boulderpeptide.org.
NASHVILLE, Tenn. & NORTH AUGUSTA, S.C.--(BUSINESS WIRE)--Amytrx Therapeutics, a mission-driven biopharmaceutical company dedicated to commercializing transformative and cutting-edge human anti-inflammatory peptides, has expanded their bioactive peptide platform beyond the original lead therapeutic molecule to include a multi-purpose drug delivery vehicle and imaging agent. In its recently completed Phase I/IIa clinical trial as part of an FDA-approved adaptive Phase I/II clinical protocol, AMTX-100 has shown great potential in rapidly improving outcomes for patients with the inflammatory skin disorder, atopic dermatitis (AD). A Phase IIb in adult subjects with mild to moderate AD is planned to start in 3Q 2022. Preclinical studies conducted for AMTX-100 to date allow for additional skin indications to start as Phase II trials. Amytrx is targeting additional studies in adolescent mild to moderate AD, psoriasis, lupus, rosacea, acne, shingles, herpes, and re-epithelialization/healing after chemical peels. Further, with its recent pre-clinical and clinical progress, Amytrx has identified new opportunities for other inflammatory and metabolic diseases with attractive out-licensing and collaborative opportunities using its proprietary AMTX-100 human peptide platform.
The advantages which AMTX-100 provides are twofold. The first is its unique specificity to target leukocytes involved in the overactive immune response and the second is its ability to cross cell membranes and enter the nucleus through natural mechanisms already utilized by cells. As such, the resulting peptide platform shows great promise in a wide range of therapeutic and delivery applications in inflammation, autoimmunity, and cancer. This comes on the heels of Amytrx Therapeutics’ most recent fundraising for the last tranche of its Series A round totaling $18 million to address novel human peptide interventions for AD and other skin disorders.
PLG0206 has the potential to be the first approved therapy specifically indicated for the treatment of periprosthetic joint infection
PITTSBURGH--(BUSINESS WIRE)--Peptilogics, a biotech company engineering peptide therapeutics to improve the treatment landscape for patients with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s lead drug candidate, PLG0206, for the treatment of periprosthetic joint infection (PJI).
“Total joint replacements are the most common major surgical procedure performed annually across the globe. At any time following surgery, patients can develop PJI, a devastating and life-threatening condition with suboptimal treatment options and a high mortality rate,” said David Huang, M.D., Ph.D., Chief Medical Officer of Peptilogics. “Receiving the FDA’s Fast Track designation supports our efforts to improve the standard of care for those impacted by PJI. We look forward to continuing to evaluate PLG0206’s potential to address the unique challenges of the disease and help patients in need.”
Biosynth Carbosynth (“Biosynth”), a supplier of critical products and services to the life sciences industry, announces today the acquisition of Pepscan, an expert provider of peptide-based products & services.
Biosynth’s ability to deliver chemical manufacturing services “from the first idea to the finished product” is now matched in peptides, with Pepscan’s expertise in both lead discovery & optimization and GMP production combining with the capabilities of vivitide, the US peptide specialists, which joined Biosynth in March.
The two companies will form Biosynth’s new Peptide division, with broad capabilities and offering to the pharma & biotech, diagnostics and cosmetics industries, and their academic counterparts. Pepscan also brings proprietary technologies, like its patented CLIPS™ technology, which locks peptides into active conformations. CLIPS™ peptides are applied for lead discovery and optimization, as well as in its epitope mapping platform.
PARIS--(BUSINESS WIRE)--Iktos, a company specialized in Artificial Intelligence for new drug design, today announced a research collaboration with Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company changing lives with innovative peptide-based medicines to co-develop generative and predictive AI technologies for peptide drug design.
Iktos’ AI technology, based on a comprehensive data-driven chemical structure generation technology, brings new insights into the drug discovery process. This technology automatically designs virtual novel molecules with all the characteristics of a successful drug molecule. Iktos has recently diversified its R&D efforts into the development of an AI technology for peptide-based therapeutics and has developed state-of-the-art generative and predictive models to facilitate design of novel peptide therapeutics with desired properties.
Read the full article on BUSINESSWIRE.COM
Missed seeing the August VBPS event on the Design of PCSK9 Inhibitor Peptides? Have no fear, the videos are here!
On August 2nd, Chengwei Wu and Li Li, both from Merck Research Laboratories, each gave a talk on how helped to develop an orally bioavailable, tricyclic peptide PCSK9 inhibitor. Each speaker presented for 30 minutes followed by a moderated panel discussion and Q&A session.
Recordings of the seminar are available at www.boulderpeptide.org/virtual-bps/. *Please note - you must be logged in to the Boulder Peptide website to access the link*
These educational e-seminars are provided free of charge by the Boulder Peptide Foundation. If your company is interested in supporting this or other educational initiatives, please email sponsorship@boulderpeptide.org.
The September BPF Virtual Symposium will feature John Mumm, founder and CEO of Deka Biosciences, and Gaurav Bhardwaj, Assistant Professor of Medicinal Chemistry at the University of Washington and the Institute for Protein Design, speaking on how they are using peptides to target interleukin receptors. Each speaker will present for 30 minutes followed by a moderated panel discussion when attendees will have a chance to submit and ask questions.
Registration is free, and can be completed at Virtual BPS | Boulder Peptide Symposium. *Note* you must be signed in to the site inorder to sign up.
These educational e-seminars are provided free of charge by the Boulder Peptide Foundation. If your company is interested in supporting this or other educational initiatives, please email sponsorship@boulderpeptide.org.
Completed Phase I dose escalation; results expected in 3Q22
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Jun. 8, 2022-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the first patient has been dosed in the expansion portion of the Phase I/II study of BT5528, Bicycle’s second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2.
“We believe EphA2 is an attractive target for cytotoxin delivery and BT5528 has the potential to overcome the significant safety concerns seen with an antibody drug conjugate (ADC) approach to targeting EphA2,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. “We are pleased with the molecule’s emerging safety profile and early signs of anti-tumor activity and look forward to providing additional data from the completed Part A portion of the Phase I/II trial next quarter.”
READ FULL PRESS RELEASE AT BICYCLE THERAPEUTICS
A recent phase 1/2 study under review at the Nature Portfolio journal and posted to the Research Square* preprint server demonstrated that a peptide-centered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell activator, CoVac-1, was efficient in B-cell deficient people.
The SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic prompted the invention of numerous vaccinations that safeguard billions of humans from the disease's severe course, primarily through the generation of humoral or antibody-triggered immunity. T-cell immunity is critical for controlling SARS-CoV-2 infection, especially in individuals who cannot generate a humoral immune response to a prophylactic vaccination or natural infection. Individuals with inherited B-cell deficiency and cancer patients with treatment- or disease-linked B cell reduction fall into this category. T cells are crucial for COVID-19 outcomes and SARS-CoV-2 immunity maintenance in addition to B cell-driven humoral immunity.
TO READ THE FULL ARTICLE VISIT NEWS-MEDICAL.NET
The first batch of financing lasted about five years, but this time around, Sapience Therapeutics thinks its new funding round will have runway for less than two years, until the back half of 2023.
That’s because the Harrison, NY biotech has clinical programs to fund. So, NexPoint is joining existing backers Bristol Myers Squibb, Eshelman Ventures and Kingdon Capital in supplying $41 million for a Series B.
Sapience is going after so-called undruggable targets in cancer by developing small peptides that target protein-protein interactions in the cytoplasm and nucleus. Specifically, Sapience thinks it has the science and tech to go after targets that have been known for decades as “molecular underpinnings” driving cancer but have been unattainable for successful treatments, founder and CEO Barry Kappel told Endpoints News.
READ FULL ARTICLE ON ENDPOINTS NEWS